Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Provided By GlobeNewswire
Last update: May 1, 2025
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment
of Focal Segmental Glomerulosclerosis (FSGS)
